193 related articles for article (PubMed ID: 24220052)
1. Liver natural killer cell inoculum for liver transplantation with hepatocellular carcinoma.
Nishida S; Levi DM; Tzakis AG
Curr Opin Organ Transplant; 2013 Dec; 18(6):690-4. PubMed ID: 24220052
[TBL] [Abstract][Full Text] [Related]
2. Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma.
Ohira M; Nishida S; Tryphonopoulos P; Tekin A; Selvaggi G; Moon J; Levi D; Ricordi C; Ishiyama K; Tanaka Y; Ohdan H; Tzakis AG
Cell Transplant; 2012; 21(7):1397-406. PubMed ID: 22469170
[TBL] [Abstract][Full Text] [Related]
3. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans.
Ishiyama K; Ohdan H; Ohira M; Mitsuta H; Arihiro K; Asahara T
Hepatology; 2006 Feb; 43(2):362-72. PubMed ID: 16440347
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
[TBL] [Abstract][Full Text] [Related]
5. Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma.
Ohira M; Hotta R; Tanaka Y; Matsuura T; Tekin A; Selvaggi G; Vianna R; Ricordi C; Ruiz P; Nishida S; Tzakis AG; Ohdan H
Cancer Immunol Immunother; 2022 Mar; 71(3):589-599. PubMed ID: 34282496
[TBL] [Abstract][Full Text] [Related]
6. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
7. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
[TBL] [Abstract][Full Text] [Related]
8. Possibility of adoptive immunotherapy with peripheral blood-derived CD3⁻CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity.
Doskali M; Tanaka Y; Ohira M; Ishiyama K; Tashiro H; Chayama K; Ohdan H
J Immunother; 2011 Mar; 34(2):129-38. PubMed ID: 21304407
[TBL] [Abstract][Full Text] [Related]
9. Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy.
Liu P; Chen L; Zhang H
J Immunol Res; 2018; 2018():1206737. PubMed ID: 30255103
[TBL] [Abstract][Full Text] [Related]
10. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells.
Kajitani K; Tanaka Y; Arihiro K; Kataoka T; Ohdan H
Breast Cancer Res Treat; 2012 Jul; 134(1):139-55. PubMed ID: 22261932
[TBL] [Abstract][Full Text] [Related]
12. Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma.
Zhuang L; Fulton RJ; Rettman P; Sayan AE; Coad J; Al-Shamkhani A; Khakoo SI
Hepatol Int; 2019 Jan; 13(1):75-83. PubMed ID: 30467624
[TBL] [Abstract][Full Text] [Related]
13. Taste receptor T1R1/T1R3 promotes the tumoricidal activity of hepatic CD49a
Liu S; Xu M; Zhu C; Zhao Q; Zhou F
Eur J Immunol; 2018 Dec; 48(12):2031-2041. PubMed ID: 30259960
[TBL] [Abstract][Full Text] [Related]
14. Donor Age Correlates With Liver-Resident Natural Killer Cell Activity in Adoptive Immunotherapy Using Donor Liver Natural Killer Cells in Liver Transplantation.
Ohira M; Imaoka K; Bekki T; Sato K; Imaoka Y; Nakano R; Yano T; Doskali M; Shimizu S; Chogahara I; Sato S; Nakamura M; Tanaka Y; Ohdan H
Transplant Proc; 2024 Apr; 56(3):667-671. PubMed ID: 38326202
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cells in the treatment of high-risk acute leukaemia.
Locatelli F; Moretta F; Brescia L; Merli P
Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
[TBL] [Abstract][Full Text] [Related]
17. Expansion and activation of natural killer cells from PBMC for immunotherapy of hepatocellular carcinoma.
Peng BG; Liang LJ; He Q; Huang JF; Lu MD
World J Gastroenterol; 2004 Jul; 10(14):2119-23. PubMed ID: 15237448
[TBL] [Abstract][Full Text] [Related]
18. Liver transplantation for hepatocellular carcinoma: lessons learned and future directions.
Levi DM; Nishida S
Clin Liver Dis; 2011 Nov; 15(4):717-25. PubMed ID: 22032525
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
[TBL] [Abstract][Full Text] [Related]
20. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]